Licensing & partnership
Boston Scientific Prices Note Offerings
Boston Scientific priced $3 billion in U.S. dollar-denominated notes, while its finance subsidiary priced €4.25 billion in euro-denominated notes. The company intends to use the proceeds, alongside other funding sources, primarily to finance the cash consideration for its proposed acquisition of Penumbra and related expenses.
The offerings are expected to close on December 1, 2026. Except for the floating-rate notes, the notes are subject to special mandatory redemption if the acquisition does not proceed under specified conditions.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.